Trial Search Results

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

The purpose of this trial is to study giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery. Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving oxaliplatin, leucovorin calcium, and fluorouracil is more effective with or without celecoxib in treating colon cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Alliance for Clinical Trials in Oncology

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: celecoxib
  • Drug: 5-fluorouracil
  • Other: placebo
  • Drug: oxaliplatin
  • Drug: leucovorin

Phase:

Phase 3

Eligibility


1. Requirements for tumor parameters

      1. Histologically documented adenocarcinoma of the colon. The gross inferior
      (caudad) margin of the primary tumor must lie above the peritoneal reflection
      (i.e., patients with rectal cancer are not eligible). Surgeon confirmation that
      the entire tumor was above the peritoneal reflection is only required in cases
      where it is important to establish if the tumor is a rectal or colon primary.

      2. Tumors must have been completely resected. In patients with tumor adherent to
      adjacent structures, en bloc R0 resection must be documented in the operative
      report or otherwise confirmed by the surgeon. Near or positive radial margin are
      not exclusions as long as en bloc resection was performed. Positive proximal
      margin or distal margin is an exclusion.

      3. Node positive disease (N1 or N2) as designated in AJCC version 7. Either at least
      one pathologically confirmed positive lymph node or N1C (defined as tumor
      deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or
      perirectal tissues without regional lymph node metastases). Patients with
      resected stage IV disease are not eligible.

      4. No evidence of residual involved lymph node disease or metastatic disease at the
      time of registration.

      5. Patients with synchronous colon cancers are eligible and staging for
      stratification will be based on higher N stage of the more advanced primary
      tumor. However, patients with synchronous colon and rectal primary tumors are not
      eligible.

   2. NSAID use

   Patients are ineligible if they plan on regular use of NSAIDs at any dose more than 2
   times per week (on average) or aspirin at more than 325 mg at least three times per
   week, on average. Low-dose aspirin not exceeding 100 mg/day is permitted. Patients who
   agree to stop regular NSAIDs or higher dose aspirin are eligible and no was out period
   is required.

   3. Patient history

      1. No previous or concurrent malignancy, except treated basal cell or squamous cell
      cancer of skin, treated in situ cervical cancer, treated lobular or ductal
      carcinoma in situ in one breast, or any other cancer for which the patient has
      been disease-free for at least 5 years.

      2. No neurosensory or neuromotor toxicity ≥ grade 2 at the time of registration.

      3. No known allergy to platinum compounds.

      4. No prior allergic reaction or hypersensitivity to sulfonamides, celecoxib or
      NSAIDs.

      5. No history of upper gastrointestinal ulceration, upper gastrointestinal bleeding,
      or upper gastrointestinal perforation within the past 3 years. Patients with
      ulceration, bleeding or perforation in the lower bowel are not excluded.

      6. No symptomatic pulmonary fibrosis or interstitial pneumonitis ≥ grade 2.

      7. No cardiac risk factors including:

         - Uncontrolled high blood pressure (systolic blood pressure > 150).

         - Unstable angina.

         - History of documented myocardial infarction or cerebrovascular accident.

         - New York Heart Association class III or IV heart failure.

   4. Pregancy/nursing status

   Non-pregnant and not nursing. Men and women of childbearing potential must agree to
   employ adequate contraception for the duration of chemotherapy and for as many as 8
   weeks after the completion of chemotherapy due to the unknown teratogenic effects of
   FOLFOX on the developing fetus.

   5. Age and performance status

      1. ECOG performance status 0, 1 or 2.

      2. Age at least 18 years.

   6. Required initial laboratory values

      1. Granulocytes ≥ 1,500/μL

      2. Platelet count ≥ 100,000/μL

      3. Creatinine ≤ 1.5 times upper limit of normal (ULN)

      4. Total Bilirubin ≤ 1.5 times ULN in the absence of Gilbert's disease

      5. Direct bilirubin ≤ 1.5 x upper limit of normal for patients with Gilbert's
      syndrome

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting